the australian - poh oxy deal coming, page-29

Oxy deal is worth a motza.

Purdue Pharam is the largest player in the Oxy market at $3.5B in sales. Purdue was in the past previously fined $634 Million for various labelling and marketing offences from its drug Oxycontin which lead to abuse. Further US litigation against Purdue by the states may also be in the pipeline.

US DEA is also acknowledging the Oxy abuse problem but has no idea on how to fix it. ( If you are interested I'd encourage all of you to read the Purdue Pharam address to the US senate Inquiry back in early 2000 on the abuse issue.)

Use a POH matrix patch when delivering Oxy and we are led to beleieve that there is no more abuse problem. The POH technology will quickly dominate the market as individual US doctors can also get prosecuted on abuse cases.

But the highlight of my post is that if you divide the quantum of the fine against the shares on issue for POH you get roughly $0.82 per share which Purdue threw away.

Its not rocket science to work out that this thing is undervalued.